Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
June 26th 2025Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.